Affichage 1 à 10 des 13 essais cliniques
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
---|---|---|---|
Essai avec répartition aléatoire de phase III sur la durée du traitement anti-PD-1 dans le mélanome métastatique (STOP-GAP)
ME13 NCT02821013 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Mélanome |
Dr Catalin Mihalcioiu Ann Bartulovic 514-934-1934 poste 35033 |
Étude sur les marges d’excision des mélanomes de stade II – Étude de phase II multicentrique à répartition aléatoire et contrôlée évaluant les marges d’excision chirurgicales d’une largeur de 1 cm ou de 2 cm pour les mélanomes cutanés primaires de stade II selon l’AJCC.
ME15 NCT03860883 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Mélanome |
Dre Cindy Boulanger-Gobeil Maryse Gingras 418-691-5781 |
(EN) A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
MONETTE NCT05061134 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Mélanome |
Dr Joël Claveau Véronique Jobin 418-525-4444 poste 15780 |
(EN) Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
MIMic NCT03772899 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Mélanome |
Dr Wilson Miller Sarah Kassis 514-340-8222 poste 22075 |
(EN) Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 ![]() |
CISSS DE LA MONTEREGIE-CENTRE
![]() |
Mélanome Poumon non à petites cellules |
Dre Nathalie Daaboul Marilyn Tessier 450-466-5000 poste 7691 |
(EN) A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanoma
STARBOARD (KEYNOTE-B80) NCT04657991 ![]() |
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
![]() |
Mélanome |
Dr José Luiz Miranda Guimaraes Sabrina Côté 418-541-1000 poste 3065 |
(EN) Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Mélanome Poumon non à petites cellules |
Dr Bertrand Routy Wiam Belkaid 514-890-8000 |
(EN) A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy
ARTISTRY-6 NCT04830124 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Mélanome |
Dre Rahima Jamal Samantha Gennevois 514-890-800 poste 31523 |
(EN) An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
SGNS40-002 (KEYNOTE-C86) NCT04993677 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Mélanome Poumon non à petites cellules |
Dr Olivier Dumas Mélanie Croussette 418-525-4444 poste 22637 |
(EN) A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy
GO42273 NCT04835805 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Mélanome |
Dr Wilson Miller Daria Krutauz 514-340-8222 poste 24301 |